Market
Shares priced at $14 each; company to list on Nasdaq under 'TRXB' Eli Lilly is the largest shareholder, with about 24% stake

Immunology drug developer TrexBio has set the price for its initial public offering (IPO) and is preparing to list on Nasdaq.
According to BioPharma Dive on the 8th (local time), TrexBio will raise $117 million by issuing 8,333,334 shares at $14 each. That is at the low end of the range it proposed earlier this week.
The company will begin trading on Nasdaq on the 9th under the ticker symbol 'TRXB'.
TrexBio develops drugs to treat disease by calming an overactive immune system. Its approach activates regulatory T cells (Tregs), which help prevent the body from attacking itself and support wound healing.
Its lead candidate, TRB-061, is a fusion protein that targets tumor necrosis factor receptor 2 (TNFR2) on Tregs. It is designed to reduce inflammation in the skin and gut and is currently in a phase 1 trial. The company said in regulatory filings that data for the primary endpoint are expected in 2027.
TRB-071, a candidate for inflammatory bowel disease, could enter trials next year. It targets CD30, another receptor on Tregs, to increase Treg activity while blocking another source of inflammation.
TrexBio has partnered with Eli Lilly and Johnson & Johnson to discover new anti-inflammatory drugs. The pharmaceutical companies have licensed candidates discovered by TrexBio or exercised development rights.
Eli Lilly is TrexBio's largest shareholder, with about a 24% stake before the IPO. The company has also indicated that it is willing to buy additional IPO shares. TrexBio has raised $220 million in venture funding to date and secured $50 million early this year to support its phase 1 trial.
Meanwhile, Retention Pharmaceuticals also completed an upsized $45 million IPO on the same day. In a report dated the 5th, investment firm William Blair said that, taken together, recent IPOs, reverse mergers and SPAC transactions indicate that investment in the biotech public offering market in 2026 has "accelerated at an unprecedented pace."
According to BioPharma Dive data, six of the 23 drug developers that went public this year (more than 25%) are developing treatments for immunologic diseases.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Charles River Acquires Two Frontage Bioanalytical Laboratories for $470 Million

Sanofi-Backed Windward Raises $225 Million in IPO to Develop Respiratory Drugs From China

PharmaResearch Reports Third-Quarter Operating Profit of KRW 186.4 Billion, Up 14.7% Year Over Year

Hanmi Pharmaceutical’s Operating Profit Reaches ₩222.6 Billion in First Three Quarters, Up 27.5% Year Over Year

Kolon TissueGene Posts 73.3 Billion Won in Net Income Through Q3, Returns to Profit

BlueMtec Posts 5.5 Billion Won in Net Income Through Q3, Returning to Profit From a Year-Earlier Loss